We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low Serum Phosphate Linked to Risk of Heart Attack

By LabMedica International staff writers
Posted on 22 Nov 2017
Print article
Image: Variations in phosphate levels in the blood may pose risk to cardiovascular health (Photo courtesy of Dr. Steve Petryk).
Image: Variations in phosphate levels in the blood may pose risk to cardiovascular health (Photo courtesy of Dr. Steve Petryk).
Cardiovascular disease is a leading cause of mortality and morbidity worldwide, and high serum phosphate is an established risk factor for coronary artery disease, particularly in patients with chronic kidney disease.

Phosphate is an important mineral in the body and helps to regulate blood biochemistry, which can impact on the working of the heart. It plays a crucial role in enabling red blood cells to deliver oxygen to the body's tissues, and can be found in protein rich foods such as meat, poultry and fish.

Scientists at the University of Surrey (Guildford, UK) used data from the Royal College of General Practitioners (RCGP) Research and Surveillance Centre, and examined phosphate levels of more than 100,000 patients, over five and nine-year intervals, and the impact on their cardiac health. Patients aged between 18 and 90 years were included in the study. Influential demographic and physiological variables were identified for each patient as close as possible to time zero and before any cardiac event.

The physiological variables included systolic blood pressure, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, renal function (eGFR), diabetes status and blood markers HbA1c, corrected calcium, sodium, potassium, and albumin. In all cases, single measurements were used except for corrected calcium, which was recorded in a similar manner to serum phosphate with extraction of values recorded on the same dates as serum phosphate.

The investigators found that those with low levels (less than 0.75 mmol/L) of the mineral in their blood were at a similar risk of developing coronary problems as those with elevated levels (above 1.5 mmol/L). Instances of both conditions were high amongst those with low and excessive levels of phosphate in the blood; however cardiac events in those with mid-range (1-1.25 mmol/L) levels were significantly less. The present demonstrated that low, high-normal, and high serum phosphate were associated with primary cardiac disease events in a U-shaped relationship within a general UK population.

Andrew McGovern, MD, a co-author of the study, said, “Our findings shed new light on the role of phosphate in the body and its relationship to cardiovascular health. In light of our findings we would suggest that clinicians consider people with low phosphate levels to be at higher cardiovascular risk and assess ways in which this can be reduced for each patient.” The study was published on November 8, 2017, in the journal Public Library of Science ONE.

Related Links:
University of Surrey

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.